{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:40:42Z","timestamp":1792197642884,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"DOI":"10.1007\/s11523-026-01253-w","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:36:03Z","timestamp":1789533363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8349-9200","authenticated-orcid":false,"given":"Wendy","family":"Stock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Gokbuget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Vandendries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Braniff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"3","key":"1253_CR1","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood. 2007;109(3):944\u201350. https:\/\/doi.org\/10.1182\/blood-2006-05-018192.","journal-title":"Blood"},{"issue":"12","key":"1253_CR2","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","volume":"101","author":"N G\u00f6kbuget","year":"2016","unstructured":"G\u00f6kbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524\u201333. https:\/\/doi.org\/10.3324\/haematol.2016.144311.","journal-title":"Haematologica"},{"issue":"4","key":"1253_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/hon.2910","volume":"39","author":"JM Ribera","year":"2021","unstructured":"Ribera JM, Morgades M, Genesc\u00e0 E, Chapchap EC, Montesinos P, Acu\u00f1a-Cruz E, et al. Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. Hematol Oncol. 2021;39(4):529\u201338. https:\/\/doi.org\/10.1002\/hon.2910.","journal-title":"Hematol Oncol"},{"issue":"9","key":"1253_CR4","doi-asserted-by":"publisher","first-page":"E245","DOI":"10.1002\/ajh.25896","volume":"95","author":"B Samra","year":"2020","unstructured":"Samra B, Alotaibi AS, Short NJ, Khoury JD, Ravandi F, Garris R, et al. Outcome of adults with relapsed\/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. 2020;95(9):E245\u20137. https:\/\/doi.org\/10.1002\/ajh.25896.","journal-title":"Am J Hematol"},{"issue":"2 Pt A","key":"1253_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.molimm.2014.09.014","volume":"67","author":"B Shor","year":"2015","unstructured":"Shor B, Gerber HP, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67(2 Pt A):107\u201316. https:\/\/doi.org\/10.1016\/j.molimm.2014.09.014.","journal-title":"Mol Immunol"},{"issue":"5","key":"1253_CR6","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","volume":"103","author":"JF DiJoseph","year":"2004","unstructured":"DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807\u201314. https:\/\/doi.org\/10.1182\/blood-2003-07-2466.","journal-title":"Blood"},{"issue":"7","key":"1253_CR7","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2013","unstructured":"Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165\u201374. https:\/\/doi.org\/10.1182\/blood-2012-06-438002.","journal-title":"Blood"},{"issue":"14","key":"1253_CR8","first-page":"3336","volume":"53","author":"LM Hinman","year":"1993","unstructured":"Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993;53(14):3336\u201342.","journal-title":"Cancer Res"},{"issue":"14","key":"1253_CR9","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gokbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474\u201387. https:\/\/doi.org\/10.1002\/cncr.32116.","journal-title":"Cancer"},{"issue":"8","key":"1253_CR10","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1509277.","journal-title":"N Engl J Med"},{"key":"1253_CR11","unstructured":"FDA approves inotuzumab ozogamicin for relapsed or refractory B-cell precursor ALL. Accessed. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-inotuzumab-ozogamicin-relapsed-or-refractory-b-cell-precursor-all (2017)."},{"key":"1253_CR12","unstructured":"BESPONSA (inotuzumab ozogamicin) PI. Accessed. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761040s000lbl.pdf (2017)."},{"issue":"16_suppl","key":"1253_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e18536","volume":"43","author":"A Dixit","year":"2025","unstructured":"Dixit A, Sahu S, Iftikhar S, Mareedu T, Bhasin PG, Chandra P, et al. Assessing the impact of high body mass index on acute lymphoblastic leukemia: a 30-year global analysis. J Clin Oncol. 2025;43(16_suppl):e18536-e. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e18536.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1253_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1182\/bloodadvances.2023011862","volume":"8","author":"H Johnston","year":"2023","unstructured":"Johnston H, Youshanlouei HR, Osei C, Patel AA, DuVall A, Wang P, et al. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2023;8(1):164\u201371. https:\/\/doi.org\/10.1182\/bloodadvances.2023011862.","journal-title":"Blood Adv"},{"issue":"18","key":"1253_CR15","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1182\/bloodadvances.2023009976","volume":"7","author":"S Shimony","year":"2023","unstructured":"Shimony S, Flamand Y, Valtis YK, Place AE, Silverman LB, Vrooman LM, et al. Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. Blood Adv. 2023;7(18):5234\u201345. https:\/\/doi.org\/10.1182\/bloodadvances.2023009976.","journal-title":"Blood Adv"},{"key":"1253_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153886","author":"P Gogia","year":"2023","unstructured":"Gogia P, Ashraf H, Bhasin S, Xu Y. Antibody-drug conjugates: a review of approved drugs and their clinical level of evidence. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15153886.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1253_CR17","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/cpt.2278","volume":"110","author":"MZ Liao","year":"2021","unstructured":"Liao MZ, Lu D, K\u00e5gedal M, Miles D, Samineni D, Liu SN, et al. Model-informed therapeutic dose optimization strategies for antibody-drug conjugates in oncology: what can we learn from US Food and Drug Administration-approved antibody-drug conjugates? Clin Pharmacol Ther. 2021;110(5):1216\u201330. https:\/\/doi.org\/10.1002\/cpt.2278.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1253_CR18","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","volume":"4","author":"HM Kantarjian","year":"2017","unstructured":"Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4(8):e387\u201398. https:\/\/doi.org\/10.1016\/S2352-3026(17)30103-5.","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"1253_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.18053\/jctres.03.2017S1.006","volume":"3","author":"J Massart","year":"2017","unstructured":"Massart J, Begriche K, Moreau C, Fromenty B. Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res. 2017;3(Suppl 1):212\u201332. https:\/\/doi.org\/10.18053\/jctres.03.2017S1.006.","journal-title":"J Clin Transl Res."},{"issue":"15","key":"1253_CR20","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","volume":"1","author":"DJ DeAngelo","year":"2017","unstructured":"DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study. Blood Adv. 2017;1(15):1167\u201380. https:\/\/doi.org\/10.1182\/bloodadvances.2016001925.","journal-title":"Blood Adv"},{"issue":"8","key":"1253_CR21","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3324\/haematol.2024.286091","volume":"110","author":"M Ozcan","year":"2025","unstructured":"Ozcan M, Cassaday RD, Zarzycka E, Vandendries E, Zhang F, Chen Y, et al. Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study. Haematologica. 2025;110(8):1736\u201346. https:\/\/doi.org\/10.3324\/haematol.2024.286091.","journal-title":"Haematologica"},{"issue":"1","key":"1253_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1055\/s-2002-23204","volume":"22","author":"LD DeLeve","year":"2002","unstructured":"DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22(1):27\u201342. https:\/\/doi.org\/10.1055\/s-2002-23204.","journal-title":"Semin Liver Dis"},{"issue":"7","key":"1253_CR23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906\u201312. https:\/\/doi.org\/10.1038\/bmt.2016.130.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"1253_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10928-018-9614-9","volume":"46","author":"M Garrett","year":"2019","unstructured":"Garrett M, Ruiz-Garcia A, Parivar K, Hee B, Boni J. Population pharmacokinetics of inotuzumab ozogamicin in relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. J Pharmacokinet Pharmacodyn. 2019;46(3):211\u201322. https:\/\/doi.org\/10.1007\/s10928-018-9614-9.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"1253_CR25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.metabol.2005.11.004","volume":"55","author":"J Verbraecken","year":"2006","unstructured":"Verbraecken J, Van de Heyning P, De Backer W, Van Gaal L. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism. 2006;55(4):515\u201324. https:\/\/doi.org\/10.1016\/j.metabol.2005.11.004.","journal-title":"Metabolism"},{"issue":"7","key":"1253_CR26","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1158\/1078-0432.CCR-16-0939","volume":"23","author":"M Guffroy","year":"2017","unstructured":"Guffroy M, Falahatpisheh H, Biddle K, Kreeger J, Obert L, Walters K, et al. Liver microvascular injury and thrombocytopenia of antibody-calicheamicin conjugates in cynomolgus monkeys-mechanism and monitoring. Clin Cancer Res. 2017;23(7):1760\u201370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0939.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1253_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41409-023-02154-6","volume":"59","author":"LK Gjaerde","year":"2024","unstructured":"Gjaerde LK, Ruutu T, Peczynski C, Boreland W, Kroger N, Blaise D, et al. The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party. Bone Marrow Transplant. 2024;59(2):255\u201363. https:\/\/doi.org\/10.1038\/s41409-023-02154-6.","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"1253_CR28","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1200\/jco.21.00471","volume":"39","author":"JJ Griggs","year":"2021","unstructured":"Griggs JJ, Bohlke K, Balaban EP, Dignam JJ, Hall ET, Harvey RD, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. J Clin Oncol. 2021;39(18):2037\u201348. https:\/\/doi.org\/10.1200\/jco.21.00471.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1253_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(24)00316-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1253_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3109\/10428194.2015.1136741","volume":"59","author":"E Orgel","year":"2018","unstructured":"Orgel E, Mueske NM, Sposto R, Gilsanz V, Freyer DR, Mittelman SD. Limitations of body mass index to assess body composition due to sarcopenic obesity during leukemia therapy. Leuk Lymphoma. 2018;59(1):138\u201345. https:\/\/doi.org\/10.3109\/10428194.2015.1136741.","journal-title":"Leuk Lymphoma"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01253-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01253-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01253-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:55:54Z","timestamp":1792194954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01253-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":30,"alternative-id":["1253"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01253-w","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original version, corrections to table 1 updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Wendy Stock reports consulting\/advisory services for Astra Zeneca, Servier, Jazz Pharmaceuticals and Newave Pharmaceutical Inc. Ryan Cassaday reports honoraria from AstraZeneca, Autolus, Cycle Pharmaceuticals, Pfizer and Takeda; consulting\/advisory services for Jazz, Merck, Pfizer, Sana Biotechnologies, Servier; is a member of the Review Board\/Committee for Autolus, and PeproMene Bio; and has received research funding from Amgen, Incyte, Jazz, Pfizer, Servier, and Takeda. Daniel J. DeAngelo reports consulting\/advisory services for Amgen, Autolos, Blueprint, Gilead, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, and Takeda; and and has received research funding from Abbvie, Glycomimetics, Novartis and Blueprint Pharmaceuticals, and serves on the DSMB for Daiichi-Sankyo, and Mt Sinai MPN Consortium. Anjali Advani reports serving on the steering committee of Amgen; consulting services\/honoraria from Astrazeneca, Syndax, Kite, Servier, Takeda, Pfizer; and has received research funding from OBI Pharma, Inc., Amgen, Pfizer, Novartis, Kura, Seattle Genetics, Abbvie, Immunogen, Incyte, Servier, Macrogenics, BEAM and Stelexis. Nicola Gokbuget reports honoraria from Astra Zeneca, Autolus, Amgen, and Pfizer as well as research funding from Astra Zeneca, Autolus, Amgen, and Pfizer. Josep Ribera reports research funding from Amgen, Kite\/Gilead, Incyte, Pfizer, Servier, and Takeda. Wei Jiang is an employee of Pfizer and owns stock in Pfizer. Susana Pulido is an employee of Pfizer and owns stock in Pfizer. Erik Vandendries is an employee of Pfizer and owns stock in Pfizer. Nathan Braniff is an employee of Pfizer and owns stock in Pfizer. Elias Jabbour reports consulting\/advisory services for AbbVie, Adaptive Biotechnologies, Amgen, Autolus, Ascentage, Bristol Myers Squibb, Novartis, Takeda, Pfizer, TG-RX and TERNS; and has received research funding from Pfizer, AbbVie, Amgen, Takeda, Adaptive Biotechnologies, Ascentage, Johnson and Johnson, TGRX, TERN701 and Novartis. Hagop Kantarjian reports consulting\/advisory services\/honoraria from Amgen, Ascentage, Ipsen Biopharmaceuticals, Novartis, Pfizer, Shenzhen Target Rx, Stemline, and Takeda; and has received research funding from Amgen, Ascentage, Daiichi-Sankyo and Novartis.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves human participants and as this was a post hoc analysis of anonymized data, no ethics committee or institutional review board approvals were required; all such approvals were obtained in the original trials.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed written consent was obtained from all participants according to the Declaration of Helsinki.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}